Annoying that BGEN gets an upgrade today, and
the marketcap increases more than the total
cap of TGEN, heh. Of course we don't know that
the upgrade has anything to do with the bgen-tgen
deal.
Here is more on IMNX/TGEN from the 10k:
Rheumatoid Arthritis
Our interest in developing a gene therapy product for the treatment of rheumatoid arthritis stems from our origins as a spinout from Immunex Corporation. As part of that spinout, Immunex granted us a license to certain Immunex technology for use in the field of genetic therapy. The TNF receptor (TNFR) gene, which is the basis for Immunex's Enbrel product for the treatment of rheumatoid arthritis, was included in that license. We believe that the characteristics of AAV vectors make them well suited for delivery of genes to joints. We are in the process of conducting preclinical experiments designed to demonstrate the potential of delivering the TNFR gene to joints using AAV vectors to provide sustained, localized production of the TNFR protein. We envision an AAV-TNFR product as an attractive alternative to systemic TNFR protein therapy in patients susceptible to infection or with disease symptoms limited to one or several joints.
Relationship with Immunex Corporation
Targeted Genetics was formed in 1989 as a subsidiary of Immunex, a biopharmaceutical company developing recombinant proteins as therapeutics. In February 1992, we spun off as a separate company from Immunex and entered into a technology license agreement with Immunex. In exchange for shares of our preferred stock, which were converted into 1,920,000 shares of common stock at the time of our initial public offering, Immunex granted us a worldwide, exclusive field-of-use license for certain Immunex proprietary technology specifically applicable to our gene therapy business. This technology relates to gene identification and cloning, panels of retroviral vectors, packaging cell technology, recombinant cytokines, DNA constructs, cell lines, promoter/enhancer elements and immunological assays. In addition, the agreement required Immunex to disclose to us, until February 1999, information concerning improvements discovered or developed by Immunex relating to the transferred technology such as new techniques, biological materials, inventions, or developments. We have the option to acquire a nonexclusive, worldwide, fully paid, royalty-free license and, in some cases, an opportunity to negotiate the conversion of a nonexclusive license into an exclusive license, to these improvements. Immunex currently owns approximately 7% of our outstanding common stock.
--that was dated Dec 31st 1999.
The annual report also gives some particulars of the relationships with Elan, Celltech/Medeva, Alkermes. I don't see Sangamo, but it should be in there too. I'm using Edgar now, but you might want to get a copy of the glossy annual report from Tgen--the did the fluffy part really artsy, a collectors item. Of course the regular 10k is in a folder in the back, the useful part.
I see from the Ariad yahoo thread that Genovo does not have any of the Ariad goodies these days, I am a little disappointed to see that. Daytrader profit taking I guess today. I'll mark down a $20 target by the end of this year.
Good luck, and thanks for visiting this lonely thread, do stay awhile nogriefplz! |
